Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Authors :: Stelljes, Matthias
Alakel, Nael
Wäsch, Ralph
Scholl, Sebastian
Nachtkamp, Kathrin
Rank, Andreas
Haenel, Mathias
Spriewald, Bernd
Hanoun, Maher
Martin, Sonja
Schwab, Katjana
Knaden, Julian
Reiser, Lena
Marx, Julia
Wethmar, Klaus
Sauer, Tim
Berdel, Wolfgang E.
Lenz, Georg
Brüggemann, Monika
Raffel, Simon
Goekbuget, Nicola
Source :: Blood. 140:510-512
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools